Compare Adaptive Biotechnologies Corp (ADPT) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Direxion Daily TSLA Bull 2X Shares trades at $12.27. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| ADPT | TSLL | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $22.37 | $23.03 |
52-Week Low | $10.24 | $10.09 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
TSLL trades at $13.95, up 13.41% in the last 24 hours, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. Support levels are established at $13 and $12, with resistance near $15. Recent news highlights continued investor interest in leveraged ETF strategies tied to high-growth sectors like Tesla.
The outlook for TSLL is cautiously optimistic, driven by strong technical momentum and sector interest, but risks include market volatility and dependency on underlying asset performance. Investors should weigh the potential for amplified returns against the inherent leverage risks in the ETF structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
